Alnylam Pharmaceuticals, Inc. (ALNY): Eastern Capital Owns 3.8 Million Shares

Page 6 of 8 SEC Filing

 

CUSIP No. 02043Q107 13G/A Page 6

Item 3.  If this statement is filed pursuant
to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4.  Ownership.

Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.

The percentage ownership noted in this Schedule 13G/A is based on 85,138,602
shares outstanding as of January 29, 2016 as reported in the Issuer 10-Q filed with the U.S. Securities Exchange and Commission
on February 12, 2016.

As of the date of this filing, Eastern Capital Limited, Portfolio Services
Ltd. and Mr. Dart beneficially own in aggregate the following:

(a) Amount beneficially owned:   3,802,341
(b) Percent of class:  4.5%
(c) Number of shares as to which the person has:  
(i) Sole power to vote or to direct the vote  0
(ii) Shared power to vote or to direct the vote   3,802,341
(iii) Sole power to dispose or to direct the disposition of  0
(iv) Shared power to dispose or to direct the disposition of   3,802,341

Instruction. For computations regarding securities
which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)